Stoke Therapeutics, Inc. (STOK) Spending and interest coverage
- R&D / revenue · 12 months: Value 611.01%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 135.72%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value -4752.70×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 611.01% | Research and development expense / revenue. Period ending 2026-06-30. $168.56M ÷ $27.59M × 100 ≈ 611.01% |
| Stock-based compensation / revenue · 12 months | 135.72% | Share-based compensation / revenue. Period ending 2026-06-30. $37.44M ÷ $27.59M × 100 ≈ 135.72% |
| Interest coverage · 12 months | -4752.70× | Operating income ÷ reported interest expense. $-223.38M ÷ $47.00K ≈ -4752.70× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 168.56M USD | Research and Development Expense |
| Revenue | 27.59M USD | |
| Stock-based compensation | 37.44M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -223.38M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 47.00K USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $168.56M | $27.59M | $37.44M | $-223.38M | $47.00K | 611.01% | 135.72% | -4752.70× | Reported |
| 2026-03-31 | $144.92M | $32.08M | $34.24M | $-185.25M | $31.00K | 451.74% | 106.73% | -5975.74× | Reported |
| 2025-12-31 | $137.92M | $184.42M | $32.24M | $-20.59M | $9.00K | 74.79% | 17.48% | -2287.78× | Reported |
| 2025-09-30 | $119.65M | $205.63M | $29.53M | $27.20M | $5.00K | 58.19% | 14.36% | 5439.20× | Reported |
| 2025-06-30 | $104.16M | $199.89M | $28.98M | $40.28M | $2.00K | 52.11% | 14.50% | 20141.00× | Reported |
| 2025-03-31 | $99.44M | $190.91M | $28.81M | $38.24M | $5.00K | 52.09% | 15.09% | 7648.00× | Reported |
| 2024-12-31 | $89.13M | $36.55M | $27.47M | $-101.37M | $26.00K | 243.83% | 75.15% | -3898.92× | Reported |
| 2024-09-30 | $87.49M | $16.74M | $26.39M | $-117.31M | (m) | 522.53% | 157.61% | (m) | (m) |
| 2024-06-30 | $85.55M | $15.16M | $25.45M | $-114.53M | (m) | 564.45% | 167.89% | (m) | (m) |
| 2024-03-31 | $84.97M | $7.84M | $24.78M | $-118.45M | (m) | 1083.22% | 315.91% | (m) | (m) |
| 2023-12-31 | $82.23M | $8.78M | $25.26M | $-114.77M | (m) | 936.57% | 287.67% | (m) | (m) |
| 2023-09-30 | $81.51M | $9.25M | $24.99M | $-112.36M | (m) | 881.60% | 270.27% | (m) | (m) |
| 2023-06-30 | $81.35M | $8.84M | $24.36M | $-112.28M | (m) | 919.84% | 275.47% | (m) | (m) |
| 2023-03-31 | $79.16M | $14.56M | $23.77M | $-104.25M | (m) | 543.79% | 163.26% | (m) | (m) |
| 2022-12-31 | $77.84M | $12.40M | $22.85M | $-104.36M | (m) | 627.46% | 184.23% | (m) | (m) |
| 2022-09-30 | $72.58M | (m) | $21.75M | $-101.71M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $66.83M | (m) | $20.44M | $-97.24M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $62.56M | (m) | $18.73M | $-94.03M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $54.17M | (m) | $16.45M | $-86.06M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $47.27M | (m) | $13.34M | $-76.13M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $41.02M | (m) | $10.52M | $-67.15M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $34.90M | (m) | $7.71M | $-58.14M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $32.20M | (m) | $5.77M | $-53.04M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $30.38M | (m) | $4.90M | $-49.53M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $28.79M | (m) | $3.85M | $-45.66M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $26.85M | (m) | $2.50M | $-41.09M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $23.76M | (m) | $1.92M | $-35.68M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | $-17.19M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $8.37M | (m) | $240.00K | $-12.78M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |